Funding round
Kallyope Series C
Kallyope, which works in neurological disease therapeutics discovery in New York, raised $112M in a Series C round announced on 25 Mar 2020. 9 firms took part, 7 of them already investors. It is Kallyope's third venture round on record; the one before was a Series B in Feb 2018.
$112M
Amount raised
Not disclosed
Post-money valuation
9
Investors
no lead named
Valuation
What this round says about the price
Kallyope did not disclose a valuation in this round. It came 25 months after Kallyope's Series B. It is 24% of the $458M Kallyope has raised in the venture rounds on record. Kallyope raised again 23 months later: a Series D round of $236M in Feb 2022, at $1.30B post-money.
Investors
Who put money in
9 firms took part; no lead investor was named.
Investors
- backs 24 venture-backed companies existing investor
- Lux Capital backs 194 venture-backed companies existing investor
- backs 98 venture-backed companies existing investor
- Euclidean Capital existing investor
- Two Sigma Ventures backs 60 venture-backed companies existing investor
- backs 38 venture-backed companies existing investor
- Alexandria Venture Investments existing investor
- backs 54 venture-backed companies new investor
- Greenspring Associates new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development and scaling operations.
- Product development
- Scaling operations
Comparable rounds
How it compares
25 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $70M, and this round was 1.6 times the median. The closest in time, other companies' Series C rounds in Biotechnology:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| Biotechnology | 19 Feb 2020 | $45M | not disclosed | not named |
| Biotechnology | 6 Feb 2020 | $24M | not disclosed | PHC Holdings Corporation |
| Biotechnology | 10 Jan 2020 | $32M | not disclosed | not named |
| Biotechnology | 8 Jan 2020 | $16M | not disclosed | not named |
| Biotechnology | 17 Dec 2019 | $28M | not disclosed | Northpond Ventures |
| Biotechnology | 16 Jul 2020 | $112M | not disclosed | HP WILD Holding AG |
| Biotechnology | 24 Aug 2020 | $115M | not disclosed | RA Capital |
| Biotechnology | 15 Oct 2019 | $85M | not disclosed | Aliment Capital and Temasek |
Sources
Where this comes from
Reported by 3 sources.
Questions
Frequently asked
How much did Kallyope raise in its Series C round?
Kallyope raised $112M in its Series C round, announced in Mar 2020.
Which investors took part in Kallyope's Series C round?
The Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures and Illumina Ventures and 3 more.
What was Kallyope's valuation at the Series C round?
It was not disclosed.
How does it compare with other Series C rounds in Biotechnology?
25 Series C rounds in Biotechnology within a year either side disclosed an amount; the median was $70M, and this round was 1.6 times the median.
Did Kallyope raise again after this round?
Yes: a Series D round in Feb 2022 of $236M at $1.30B post-money.